Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D28HJI
|
|||
| Drug Name |
FF-10101
|
|||
| Synonyms |
1472797-69-5; UNII-7V7IHI0SYG; 7V7IHI0SYG; (S,E)-N-(1-((5-(2-((4-Cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)pent-4-yn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methylbut-2-enamide; SCHEMBL15584726; SCHEMBL16443760; BDBM397428; BCP23613; s8899; US9987278, Compound Reference 38; HY-109584; CS-0032038; FF 10101; FF10101; (E)-N-[(2S)-1-[5-[2-(4-cyanoanilino)-4-(propylamino)pyrimidin-5-yl]pent-4-ynylamino]-1-oxopropan-2-yl]-4-(dimethylamino)-N-methylbut-2-enamide; 2-Butenamide, N-((1S)-2-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)-5-pyrimidinyl)-4-pentyn-1-yl)amino)-1-methyl-2-oxoethyl)-4-(dimethylamino)-N-methyl-, (2E)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60; ICD-9: 205] | Phase 1/2 | [1] | |
| Company |
FUJIFILM Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H38N8O2
|
|||
| Canonical SMILES |
CCCNC1=NC(=NC=C1C#CCCCNC(=O)C(C)N(C)C(=O)C=CCN(C)C)NC2=CC=C(C=C2)C#N
|
|||
| InChI |
1S/C29H38N8O2/c1-6-17-31-27-24(21-33-29(35-27)34-25-15-13-23(20-30)14-16-25)11-8-7-9-18-32-28(39)22(2)37(5)26(38)12-10-19-36(3)4/h10,12-16,21-22H,6-7,9,17-19H2,1-5H3,(H,32,39)(H2,31,33,34,35)/b12-10+/t22-/m0/s1
|
|||
| InChIKey |
HJFSVYUFOXAVAA-YUAYGMJFSA-N
|
|||
| CAS Number |
CAS 1472797-69-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fms-like tyrosine kinase 3 (FLT-3) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Acute myeloid leukemia | ||||
| Central carbon metabolism in cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03194685) Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health. | |||
| REF 2 | A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations. Blood. 2018 Jan 25;131(4):426-438. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.